Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Time To Buy Aastrom Biosciences

Aastrom Maps Out Future For CTRM Business

On June 16, 2014, Aastrom Biosciences (ASTM) held a conference call to discuss the company's strategy plan for the recently acquired Cell Therapy and Regenerative Medicine ("CTRM") business from Sanofi (NYSE:SNY), previously known as Genzyme Biosurgery Aps. The deal closed on May 30, 2014. The deal came at a purchase price of $6.5 million, with $4.0 million payable in cash from Aastrom to Sanofi at closing and $2.5 million payable in the form of a promissory note. On the call, management outlined an aggressive yet comprehensive action plan designed to result in CTRM generating positive cash flow from operations in 2015.

…What They Got…

Before we get into Aastrom's comprehensive action

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details